InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,885.66
(
1.58%
)
Post# of 251706
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119567
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 111296

Tuesday, 08/02/2011 12:16:24 PM

Tuesday, August 02, 2011 12:16:24 PM

Post# of 251706
(MNTA)—Eliquis update from PFE’s 2Q11 CC: CEO Ian Read said PFE will submit the Eliquis NDA in AF/stroke prevention during 2H11, but Read said nothing whatsoever about submitting an NDA for Eliquis in VTE prevention. Thus, my contention in #msg-58061618 that an Eliquis NDA in VTE prevention is problematic appears to be corroborated.

If PFE (or BMY) had said that the Eliquis dossier in VTE prevention was worthy of an NDA, I might have had to adjust the numbers in Paragraph B of #msg-64862315, where I forecasted a 50-60% loss of US Lovenox sales for VTE prevention following orthopedic surgery (contributing to a 28% drop in overall US Lovenox sales). However, as things stand, the numbers in Paragraph B of #msg-64862315 need not be changed because I assumed the Lovenox share loss in this indication was entirely due to gains by Xarelto, not Eliquis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up